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Summary 
Cloned CD4 T cell lines that recognize the Ac1-16 peptide of myelin basic protein bound to 
I-A" were isolated and used to analyze the immunopathogeuesis of experimental  autoimmune 
encephalomyelitis (EAE). T helper type 1 (Thl) clones induced disease, while Th2 clones did 
not. Using variants of a single cloned Thl line, the surface expression of o~4 integrins (very 
late antigen 4 [VLA-4]) was identified as a major pathogenic factor. Encephalitogenic  clones 
and nonencephalitogenic variants differ by 10-fold in their level of surface expression of a4 integrin 
and in their ability to bind to endothelial cells and recombinant vascular cell adhesion molecule 
1 (VCAM-1). The cx4 integrin-high, disease-indudng cloned Thl T cells enter brain parenchyma 
in abundance, while ~x4 integrin-low, nonencephalitogeuic Thl cells do not. Moreover, antibodies 
to o~4 integrin, its  ligand VCAM-1,  and intercellular  adhesion  molecule 1 all influence the 
pathogenicity of this eucephalitogenic clone in vivo. The importance of the expression of VLA-4 
for encephalitogenicity is not unique to cloned T cell lines, as similar results were obtained using 
myelin basic protein-primed lymph node T  cells, o~4 integrin levels did not affect antigen 
responsiveness or production of the Thl cytokines interleukin 2, interferon 7, and lympho- 
toxin/tumor necrosis factor fl; and antibodies against o~4 integrin did not block antigen recognition 
in vitro. Thus, we conclude that surface expression of oe4 integrin is important in CD4 T cell 
entry into brain parenchyma.  A general conclusion  of these studies is that or4 integrins may 
be crucial in allowing activated effector T  cells to leave blood and enter the brain and other 
tissues to clear infections. 
C 
ell-mediated immune responses involve the donal selec- 
tion of antigen-specific CD4 T cells in draining lymph 
nodes. Once these cells have proliferated and differentiated 
to effector function, they emigrate via the efferent lymphatics 
and enter the blood stream.  For such cells to mediate their 
effector function, they must leave blood vessels and recog- 
nize antigen in the tissues. During infection, this process con- 
tributes to host defense; in autoimmunity, it leads to tissue 
damage. The process ofT cell migration from blood to tissue 
raises many questions. How do T cells enter tissues that nor- 
mally do not contain significant numbers of such cells, such 
as the central nervous system (CNS); 1 what molecules are 
involved in the emigration of T  cells from the blood;  and 
can this process be manipulated to block local inflammation? 
In infection, local signals activate endothelial cells to in- 
Abbrepiations used in this paper: CNS,  central  nervous  system;  EAE, 
experimental  autoimmune  encephalomyelitis;  ELAM-1,  endothelial 
leukocyte adhesion molecule 1; ICAM-1, intercellular adhesion molecule 1; 
LT, lymphotoxin; MBP, myelin basic protein;  VCAM-1,  vascular cell 
adhesion molecule  1; VLA-4, very late antigen  4. 
teract with leukocytes. Activated endothelium expresses en- 
dothelial leukocyte, vascular cell, and intercellular adhesion 
molecules (ELAM-1, VCAM-1, and ICAM-1),  all involved 
in leukocyte/eudothelial  cell binding (1-9).  Thus, local in- 
fection signals for leukocyte emigration, and local lympho- 
cyte activation can sustain the process by producing inflam- 
matory cytokines (5, 6, 10-17). However, when T cells specific 
for autoantigens are infused into normal mice, they can bind 
endothelium  and  enter  tissues  in  the  absence  of  local 
inflammatory-inducing signals. This suggests that activated 
effector T cells may enter all tissues in search of antigen, and 
it seems certain that such behavior is critical in host defense 
against infectious agents that do not elicit potent inflamma- 
tory responses; it could also contribute to autoimmune dis- 
ease. Indeed, Mackay et al. (18) have shown that activated 
T cells preferentially emigrate from the blood into tissues, 
while resting cells exit in lymph node high endothelial venules. 
Thus, it is crucial to understand the mechanisms by which 
activated T cells leave the blood and enter tissues. To study 
this problem, we have examined the behavior of autoreactive 
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asked what molecules are crucial for the invasive  function. 
The intact CNS of mammals, considered to be an immuno- 
logically privileged site, does not normally contain significant 
numbers of lymphocytes. Although the blood-brain barrier 
effectively excludes inert cells such as erythrocytes and resting 
T lymphocytes, recent experiments have shown that activated 
T cells can easily cross the blood-brain barrier (19-21). How- 
ever, the exact mechanism by which these lymphocytes cross 
into the CNS remains unclear,  and the molecules involved 
have not been defined. 
We have used the disease model experimental autoimmune 
encephalomyelitis (EAE) to study the question of transit of 
T lymphocytes from the blood into the CNS. EAE is charac- 
terized by acute onset of paralysis,  perivascular and paren- 
chymal infiltration  of the brain and spinal cord by mononudear 
cells,  and inflammation  in the lesions similar to a ddayed- 
type hypersensitivity reaction. EAE can be induced actively 
by priming an animal to CNS proteins like myelin basic pro- 
tein (MBP), or adoptively by injection of activated lympho- 
cytes that  are specific for these CNS antigens (22). EAE is 
dearly mediated by CD4 + T  lymphocytes. This was origi- 
nally shown in adoptive transfer studies with lymph node 
ceils (23), and more recently by isolation of encephalitogenic 
T cell clones (24, 25). In the PL/J mouse strain,  the acetylated 
NHz-terminal  nonapeptide  MBP  Acl-9  is  the  major  en- 
cephalitogenic peptide (26). Among T cell clones specific for 
the MBP peptide Acl-9, cx and B TCR gene usage is very 
restricted  (27, 28).  However, two T  cell clones that  share 
peptide specificity and have identical TCR chains can differ 
in their ability to transfer disease (28). Therefore, the TCR 
on  a  CD4 +  T  cell  does  not  by  itsdf  determine  en- 
cephalitogenicity. Furthermore, the secretion of TNF-cx also 
plays a crucial role in the pathogenesis of EAE (29-31).  It 
is not dear what aspect or aspects of EAE are influenced by 
cytokine expression. 
In this paper we address the question of T  cell entry into 
the CNS by comparing an encephalitogenic (EAE-inducing), 
MBP-specific, CD4 + T cell clone with its variants that have 
lost encephalitogenic  activity. The variant clones have decreased 
cell surface expression of a4 integrin and show very minimal 
lymphocytic infiltration of brain upon transfer.  In addition, 
injection of antibodies to or4 integrin and its ligand VCAM-1 
can inhibit  pathogenidty  of the encephalitogenic  done in 
vivo. Thus,  these studies strongly implicate a direct role of 
ol4 integrins  in the entry of activated T  cells into  normal 
CNS tissue. 
Materials  and Methods 
M/cA  PL/J,  (SJL/J  x  PL/J)Ft,  and  BALB/c (nu/nu) mice 
were purchased from The Jackson Laboratory (Bar Harbor, ME) 
or bred in our facility. They were housed in the animal facilities 
of the Howard Hughes Medical Institute,  Section of Immunobi- 
ology, Yale University  School of Medicine. 
mAbs.  MK/5 (anti-VCAM-I) (32) and PS/2 (anti-cx4 integrin) 
(33) were provided by Dr. Paul Kincade (Oklahoma  Medical Re- 
search Foundation,  Oklahoma City, OK). LPAM-I (anti-cx4 inte- 
grin (34, 35) was provided by Dr. Irving Weissman (Stanford, CA). 
C508.19G is a mAb that recognizes a clonotypic determinant  of 
the TCR on MBP-specific clone 19. It was generated according 
to a standard protocol for hybridoma production (36). Other anti- 
bodies used were YCD3-1 (anti-CD3) (37), F23.2 (anti-V~8.2) (38), 
GK1.5 (anti-CD4) (39), TIB 124-M1/89.18.7.HK (anti-CD45) (40), 
TIB 122-M1/9.3.HL.2 (anti-CD45) (40, 41), 7D4 (anti-ID2R) (42), 
M17/5.2 (anti-LFAI) (43), YN/5 (anti-ICAM-1)  (44), IM7.8.2 
PGP1 (anti-CD44) (45), ILM2-1 (anti-CD-2) (46), Y3P (anti-I-A  u) 
(47), and Lenny (polyclonal rabbit serum to E1 integrin), provided 
to us by Drs. Clayton Buck and Steven Albelda (Wistar Institute, 
Philadelphia, PA). 
Preparation of  MBP and MBP Peptide Aci-16.  peptides were syn- 
thesized on a solid phase peptide synthesizer (430A; Applied Bio- 
systems, Inc., Foster City, CA) and purified by HPLC (48). All 
peptide preparations ran as a single peak on HPLC and had the 
predicted amino acid content and molecular weight by mass spec- 
troscopy. Mouse and guinea pig MBP were purified from spinal 
cord tissue as previously described (49, 50). 
T  Cell Lines and Clones.  CD4 T  cell clones were derived as 
previously described (25, 55). In brief, PL/J or (SJL/J  x  PL/J)F1 
mice were immunized with 50 ~g whole guinea pig MBP in CFA 
in the hind foot pads and the base of the tail 50 d hter, local lymph 
nodes were removed and stimulated with syngeneic spleen ceils plus 
50 t~g/ml mouse MBP. T cell lines were obtained by stimulation 
of these cultures ("~2 x  50' T cells) every 54 d with 6  x  10' ir- 
radiated (2,700 tad) syngeneic spleen cells per T-75 flask, plus MBP 
or MBP peptide Ac1-16 (5/zg/ml), and 5 U/ml rIL,2. T cell clones 
were obtained by soft agar cloning of the lymph node cultures 3 d 
after stimulation  in vitro,  and recloned by limiting  dilution. 
Proliferation and Lymphokine Studies.  50. of various T cell clones 
were cultured  with 5  x  10  s irradiated syngeneic spleen cells as 
feeders, with and without MBP or MBP peptide Ac5-56, in 0.2-ml 
culture medium in 96-well flat-bottomed  microtiter plates. After 
48-72 h, 1 ~Ci/well [3H]thymidine was added and cells were har- 
vested 55 h later. The mean counts per minute of [3H]thymidine 
incorporation were calculated for triplicate measurements. The stan- 
dard deviations were within 50% of the mean value. The experi- 
ments  were repeated at least twice with similar results. 
Inhibition of proliferation with different antibodies was accom- 
plished by adding varying amounts of antibody into the microtiter 
wells. The plates were harvested, counted, and analyzed as described 
above. 
Lymphokine assays  were done by standard protocols. IL-4 produc- 
tion was determined using CT4S cells and 55B15, antibody to IL-4 
(52).  TNF ode units  were determined  by cytotoxicity  against 
WEHI 164 cells (53). Units of INF-~/were determined by a viral 
plaque reduction  assay using Sindbis virus on WISH cells (54). 
FACS* Analysis and Sorting.  T cells were stained by indirect 
immunofluorescence. 0.5-5  x  506 ceils were incubated with the 
primary antibodies for 30 rain at 4~  The primary antibody was 
washed away, and the cells were incubated with appropriate sec- 
ondary  antibodies  conjugated  to  fluoreseein  (goat  anti-rat  or 
anti-mouse Ig;  Hyclone Laboratories, Logan,  UT).  Ceils were 
washed and fixed with 5% paraformaldehyde. Immunofluorescent 
analysis was performed on a FACStar Plus  |  (Becton Dickinson & 
Co., Mountain  View, CA) equipped with logarithmic amplifiers. 
Peak fluorescence  intensity is the channel number out of 5,000 with 
the most fluorescent events. 
Staining for cell sorting experiments was done according to a 
standard protocol using the LPAM-5 antibody (anti-or4 integrin) 
diluted in cell culture medium phs FCS. The secondary antibody 
was a goat anti-rat  IgG (HyClone Laboratories) conjugated  to 
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according to fluorescence intensity. Cells collected were the top 
and bottom 10% of the fluorescence intensity curve. Sorted cells 
were then simulated with APC,  antigen,  and IL-2 several times 
to obtain enough cells for in vivo transfer. The phenotype of these 
sorted lines was stable in culture as assessed by functional binding 
studies and FACS  |  analysis carried out on the day of cell transfer. 
Binding to Recombinant Soluble (rs)VCAM-1.  rsVCAM-1 at 10 
/zg/ml  was coated onto appropriate 96-well plates in NaHCO3 
buffer, pH 9.2. Plates were blocked with 1% BSA in PBS. T cells 
(2.5  x  10  s) that had been pulsed with [3H]thymidine were added 
to the coated wells in triplicate. If blocking antibodies were used, 
they were added to the T cells or the coated wells 30 min before 
addition  of the T  cells to the wells. Cells were incubated  on 
the coated plates for 10 min at room temperature, washed with 
culture medium to remove unbound cells, lysed, and harvested for 
counting (55). 
EAE Induction, Scoring, and Antibody Blocking.  For testing the 
ability of T cell clones and lines to mediate EKE in vivo, varying 
numbers  of T  cells were  injected intravenously into  (PL/J  x 
SJL)F1 mice irradiated with 350 tad. Mice were observed daily by 
an unbiased observer beginning  on day 5 for signs of EAE. The 
animals were graded according to the following scale: 1, limp tail; 
2, partial hind limb paralysis; 3, complete hind limb paralysis; 4, 
hind and front limb paralysis; 5, moribund.  Animals were cared 
for in accordance with Yale University guidelines. The score for 
each group at each day is the mean disease score of at least five 
animals. The total disease  index is calculated as the sum of  the mean 
disease score at each day for a given group over the period of the 
experiment. 
For in vivo disease experiments using mAbs to block disease, 
2-3  x  107 T cells were incubated with ascites fluid containing an- 
tibodies for 30 rain before injection. Ascites fluid was standardized 
for protein concentration by spectrophotometry (X, 280 nm). Each 
antibody dose contained 12 mg of protein. Antibodies were also 
standardized for mean fluorescence  intensity staining on the T cells. 
Animals that were given multiple doses of antibody were injected 
intravenously with antibody every 3 d. 
lmraunohistology.  Animals were perfused with PBS and then 
periodate-lysine-paraformaldehyde  (PLP) through the left ventricle 
of the heart (56). Fixed brains and spinal cords were removed, al- 
lowed to soak in PLP fixative for an additional 2 h, and then in- 
fused with increasing concentrations of sucrose in phosphate buffer 
(final sucrose  concentration, 18%). Tissue was snap frozen in tissue- 
tek compound in 2-methyl butane. Tissue was cut into 7-/zm sec- 
tions. Tissue was stained with methylene blue. 
Brain and spinal cord sections were stained according to stan- 
A 
AHTI-TCR UBS.2 
19B & 19P 
NEG 
B 
RrtTI-PLPHA 4 IHTEGRIfl 
~19P 
dard protocol using goat serum and Triton X-100 as preincubation 
blockers (56). Antibodies were diluted in the goat serum and Triton 
X-100 solution, and added to the sections to incubate for 2 h. Sec- 
tions were washed and incubated with secondary antibodies con- 
jugated to horseradish peroxidase. Sections were washed and devel- 
oped with diaminobenzidine  (DAB). The counter stain is methylene 
blue. 
Results 
Cloning and Characterization of  MBP-specific T Cells.  T cells 
responding to the encephalitogenic peptide Ac1-16 of MBP 
were isolated from PL/J mice. Of five clones tested for en- 
cephalitogenicity, two of the clones were Thl cdls, estab- 
lished by the fact that they secrete large amounts of IFN-'y 
and TNF-cx and/or -B but no Ib4,  while the other three 
clones were Th2 calls, secreting Ib4 but no Ib2 or IFN-'y. 
The Thl clones induced the disease EAE when injected in- 
travenously into  irradiated  female (PL/J  x  SJL)F1 mice, 
while the three Th2 clones did not (data not shown). One 
Thl done, done 19, will be analyzed in detail in this report. 
It is a CD4 + T  cell specific for I-A  u plus MBP Ac1-16 that 
expresses  V/~8.2,  and secretes large amounts of IFN-3, and 
TNF-oe and/or -/~ upon activation. Clone 19 induces EAE 
in a reproducible and titratable fashion. 
Clone I9 Variants That Lack Encephalitogenic Activity Have 
Decreased Cell Surface or4 Integrin.  Over time in tissue cul- 
ture, certain lines of clone 19 lost encephalitogenic activity 
(called 19B [benign]). To determine the mechanism of low- 
ered encephalitogenic potential, these variants were compared 
with encephalitogenic lines of clone 19 (caLled 19P [patho- 
genic]). Both clones retained their ability to proliferate when 
stimttlated with APC plus MBP Ac1-16, their original pheno- 
type (CD4 +, TCR VBS.2 +) (Fig.  1), and produced equiva- 
lent levds of IFN-3, and TNF-(x and/or -/~ upon activation 
(data not shown). Clones 19P and 19B were then stained with 
antibodies to a wide range of surface molecules. As seen in 
Fig. 1 and Table 1, the levd of call surface expression of these 
molecules was virtually identical for the two clones with the 
exception ofol4 integrin. The disease-inducing done 19P had 
approximately three times higher levels of (x4 integrin than 
the 19B subline that lacks encephalitogenic potential. 
Selection for the or4 Integrin  High  Phenotype  of Clone  I9 
Coselects Pathogenic Potential.  Clone 1913 was sorted by FACS  | 
c 
NITI-ALPHA 4 IHTEGRIII 
j 
19B  I~..PHlel 4L 
~  ALPHA  4H 
t0~  ....  iM  .....  i~P  ......  Jt'~ 
Figure  1.  Clone  19 variants that 
lack encephalitogenic  activity  have 
decreased cell surface  ~x4 integrin, 
but equivalent  levels  of  various other 
molecules. The clones  were  stained 
on the day of transfer in in vivo 
studies. FACS  |  profiles  of variants 
of  done 19: (A) 19B and 19P stained 
with antibodies  against TCR V/~8.2 
(F23.2); (/3) 19B and 19P stained 
with antibodies  against or4 integrin 
(LPAM); (C) 19B o~4H and 1913 
ot4L stained  with antibodies  against 
cr  integrin (LPAM). These  profiles 
are from  representative  experiments. 
The staining  was repeated  numerous 
times. 
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Peak channel fluorescence staining 
on subline 
Antibody specificity  19P  19B  19Bcx4H  19Bc~4L 
-  5  5  6  5 
Anti-CD3  -*  -*  142  140 
Anti-Vfl8.2  -*  -*  108  103 
Anti-TCR (clonotype)  50  41  43  41 
Anti-CD4  673  528  621  519 
Anti-CD45  -*  -*  632  704 
Anti-IL-2 rec.  -*  -*  60  50 
Anti-LFA-1  204  262  205  276 
Anti-ICAM-1  12  13  15  12 
Anti-CD44  154  237  227  221 
Anti-CD2  ND  ND  97  95 
Anti-VLA-4  (LPAM)  14  8  17  5 
Anti-VLA-4 (PS/2)  ND  ND  26  8 
Anti-ill integfin  24  34  30  31 
Clone 19 variants that lack encephalitogenic  activity  have decreased  cell 
surface expression  of o~4 integrin, but equivalent levels  of various other 
molecules. Clones  were stained with the indicated antibody  and analyzed 
by FACS  |  Peak  channel fluorescence  is the channd number out of 1,000 
with the most fluorescent  events. These  results are from a representative 
experiment. The staining was repeated many times. 
*  FACS|  were  identical and could  be superimposed,  however,  peak 
channel fluorescence  was not recorded. 
to obtain two populations of cells, 19B a4 integrin high and 
19B a4 integrin low. This yielded four distinct populations 
of clone 19: the nonpathogenic clone 19, which had almost 
completely lost the ability to induce disease  (19B);  the o~4 
integrin high (19Bc~4H)- and low (19Bo~4L)-sorted popula- 
tions of this nonpathogenic clone 19B; and the pathogenic 
subline 191). 
The four populations of  clone 19 were expanded to sufficient 
numbers and tested for their ability to induce EAE (Fig. 2). 
As seen in Fig.  1,  the phenotype of the oe4 integrin high 
and low populations is stable  in vitro. Fig. 2 a  shows that 
at 2  x  107 cells per animal, the oe4 integrin high sublines 
were much more effective at inducing disease than those that 
were a4 integrin low. Not only was the onset of disease ear- 
lier in mice that were given the c~4 integrin high lines, but 
the  severity of disease  was  also  greatly increased in  these 
recipients. A total disease index was calculated for each sub- 
line by adding the mean disease  score at each day over the 
course of the experiment. Fig.  2 b shows the total disease 
index for each subline as a function of cell dose.  Where the 
dose-response curves overlap, the two oc4 integrin high sub- 
lines are 8-16 times more active per cell than are the two 
o~4 integrin low sublines. 
Only Pathogenic Sublines of Clone 19 Bind Strongly to En- 
dothelial Cells and VCAM-I.  For T cells to produce disease, 
30' 
7 
2  x  10  cells  per  animal 
-I 
0  I'0  20  30 
Days  After  Injection  of  Cells 
20' 
10 ￿84 
~o.  1 07  1 0 8 
Number  01  Cells  injected 
Figure 2.  The  a4  integrin 
high sublines of  done 19 are much 
better  at inducing  disease than are 
those that are o~4 integrin  low. (a) 
T cells  were  stimulated  with MBP 
Ac1-16, syngeneic  feeders,  and I1.,2 
3 d before transfer. Five animals 
in each group were given 2  x 
107 T cells intravenously.  Animals 
were scored  according  to the stan- 
dard scale  for EAE by a blind ob- 
serw. (b) A total  disease  index  was 
calculated  for each subline  of  done 
19 at each  dose  of  cells by adding 
the mean  disease  score  at each  day 
over  a given  period of time. This 
allows the potency  of each line to 
be directly  compared. (e) Clone 
19B; (A) done 19P; (ll) clone 
19B c~4H; (A) clone 19B et4L. 
they must leave the blood and enter brain parenchyma. Since 
the pathogenic subline of clone 19 expressed greater levels 
of ol4 integrin than the benign subline, we asked whether 
there was also a difference between these cell lines in binding 
to microvascular endothelial cells from rat epididymal fat pads. 
Many more cells of the 19P subline bound to the endothelial 
cell line than did cells of the 19B subline. Furthermore, anti- 
bodies to c~4 integrin reduced the binding of the 19P subline 
to approximately the levels of binding of the 19B subline. 
By contrast, antibodies to ICAM-1 and to LFA-1 significantly 
decreased the binding of both sublines of clone 19 to the en- 
dothelial cell line (data not shown). 
As VCAM-1 is the endothelial cell ligand for c~4:fll inte- 
grin (very late antigen 4 [VLA-4]), we also tested the binding 
of these different populations of clone 19 to recombinant 
soluble VCAM-1. As shown in Fig. 3, a much larger propor- 
tion of cells from the two pathogenic populations of done 
19 (19P and 19Bot4H) bound to the rsVCAM-1 molecule than 
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Figure 3.  The or4 integrin high sublines of clone 19 
(19P and 19B oe4H) bind to rsVCAM-1 more effectively 
than the or4 integrin low sublines (19B and 19B ot4L). 
rsVCAM-1 was coated onto 96-well plates for 24 h and 
the plates  were  washed  and then blocked  with  heat- 
inactivated BSA. The various sublines of clone 19 were 
pulsed with 3H for 24 h, washed, counted, and incubated 
at 37~  for 30 min with and without antibodies to o~4 
integrin. Some wells previously coated with rsVCAM-1 
were incubated for 30 min with antibodies  against VCAM-1 
(4B9). The cells were added to the coated wells in tripli- 
cate with and without antibody, and incubated for 10 min. 
The plates were then washed and the adherent cells were 
lysed and harvested. Percent specific  binding is calculated 
as: 100x  (counts in the experimental wells on rsVCAM-1 
-  the background counts of cells bound to wells coated 
with BSA)/total  counts. 
did cells of the two populations of clone 19 that expressed 
lower levels of cd integrin (19B and 19Boe4L). Moreover, 
this binding could be partially (LPAM) or completely (PS-2) 
blocked by anti-cx4 integrin and strongly inhibited by anti- 
VCAM-! (4B9) mAb. 
Pathogenic  Sublines of Clone I9 Enter Brain Parenchyma, wkile 
Benign Sublines  Enter  Ependymal Tissue.  To deteLmine  whether 
sublines of done 19 differ in invasiveness  of brain parenchyma, 
perfusion-fixed brain  tissue  was  taken from representative 
animals in the groups given the different populations of clone 
19. The brains  from the diseased animals  given clone 19P 
were extensively  infiltrated with CD4 + lymphocytes both 
in perivascular cuffs as well as in the brain parenchyma (Fig. 
4, A and B). By contrast, brains from the nondiseased animals 
given the same number of clone 19t3 showed almost no infiltra- 
tion in the perivascular area or in the brain parenchyma, but 
did show slight infiltration within the choroid plexus and 
the meninges (Fig. 4, C and D; it should be noted that the 
area photographed represents the area with the most lym- 
phocytic infiltrate).  The entire parenchyma and perivascular 
areas were basically devoid of lymphocytes. Similar results 
were obtained using spinal cord sections from diseased and 
nondiseased animals,  and from mice given clones 19Bo14H 
or 19Boe4L. Brain sections were also stained with antibodies 
to VB8.2. The great majority of the lymphocytes  in the brains 
of the diseased animals,  as well as in the meninges of the 
nondiseased animals, express CD4 and VB8.2, suggesting that 
the cells infiltrating brain in these experiments are either the 
cloned T cells that were injected or their direct progeny (Fig. 
4, E  and F). 
The Pathogenicity  of Clone 19 Can Be Inhibited  by mAbs Specific 
for or4 Integrin, VCAM-I, or ICAM-1.  To determine whether 
or4 integrin binding to VCAM-1 is crucial for disease induc- 
tion in vivo, we asked whether antibodies to c~4 integrin and 
to its ligand VCAM-1 could influence the course of EAE. 
Various antibodies were mixed with the pathogenic done 19 
and injected into irradiated (PL/J  x  SJL)F1 female mice. As 
a control, in vitro activation of clones 19Bot4H and 19Bot4L 
61  Baron et al. Figure 4.  Perfusion-fnt~ brain tissue from diseased animals given o~4 integrin high clone 19P (,4, B, E and F) and from nondiseased animals given 
a4 integrin low done 19B (C and D). It should be noted that the areas photographed of the nondiseased brains represent the areas with the gzeatest 
number of  lymphocytes.  The entire parenchyma  and perivascular areas were basically  devoid of lymphocytes.  Low-power  (A) and high-pow~ (B) views 
of brains from diseased animals stained with antibodies to CD4. Low-power  (C) and high-power (D) views of brains from nondiseased animals stained 
with antibodies to CD4. Low-power (E) and high-power (F) views of brains from diseased animals stained with antibodies to V~8.2 (F23.2). Note 
that virtually all the cells express CD4 and V~8.2. 
was examined in the presence  and absence  of antibodies against 
a4 integrin (LPAM) and CD45 ('FIB 124). As can be seen 
in Fig. 5, the proliferation of both 19B a4H and 19B o~4L 
was unaffected by antibodies to a4 integrin and CD45, while 
proliferation was blocked in the presence of antibodies against 
I-A  u (Y3P) and the TCR clonotype (19G). 
In vivo blocking studies demonstrated that antibodies to 
or4 integrin, VCAM-1, and ICAM-1 can influence both the 
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Figure 5.  The disease-inducing  subline 19B ot4H (.4) 
and  the  non-disease-inducing subline 1913 ot4L (B) 
proliferate equivalently  in response to MBP Ac1-16 plus 
syngendc  feeders.  Antibodies  against or4 integrin (LPAM 
[e]) and the isotype-matched  anti-CD-45 control anti- 
body (TIB124 [A]) used in the in vivo blocking of dis- 
ease have no effect  on this proliferative  response, while 
mAb Y3P directed  against I-A" (O) and mAb 19G (11) 
against a donotypic determinant  of the TCR were able 
to block proliferation.  2 x  104 cells were  plated in tripli- 
c.ate in 96-wall plates along with 105 syngeneic  spleen 
cells as feeders  and MBP peptide  Ac1-16  at 10 tzg/ml. The 
various antibodies were tit'rated as shown starting at 20 
pg/ml. Wells were pulsed with 3H on day 3, and har- 
vested and counted on day 4. 
time of onset and the severity of disease (Hg. 6). Treatment 
with antibody to r  integrin delayed the onset of disease 
by 2-3 d but only slightly decreased the mean peak severity 
of disease as compared with the animals that received no an- 
tibody or an isotype-matched control antibody (anti-CD44). 
The isotype control antibody to CD44 did not block dis- 
ease, and might even have accelerated the day of onset (Fig. 
6 A). Antibody to VCAM-1 had the same effect as antibody 
to c~4 integrin. Anti-VCAM-1 given once at the time of in- 
jection of the T  cell clone delayed onset of disease by 2 d; 
continued injection of anti-VCAM-1 on days 3 and 6 further 
delayed onset of disease  (Fig.  6 B).  However, peak disease 
grade was essentially the same in all groups. These results 
suggest that the antibodies to c~4 integrin and VCAM-1 are 
blocking the entrance of the cells into the CNS;  once the 
antibody disappears,  the cells can enter the CNS and cause 
disease.  It is unlikely that the antibody delays onset disease 
by depletion of cells, since decreasing the number of injected 
T cells decreases the severity of disease before it delays onset 
(data not shown), and since isotype-matched antibodies that 
bind to the cells at higher density do not have this effect. 
Furthermore, brain sections from animals given T cells to- 
gether with antibody to or4 integrin of VCAM-1, and sam- 
pled before onset of  disease at a time when the control animals 
showed clinical signs of EAE, showed the same staining pat- 
tern as animals that received done 19B (data not shown). 
Antibody to ICAM-1 markedly delayed onset of disease as 
compared with animals that received either no antibody or 
the isotype-matched control antibody to CD45 (Fig.  6 C), 
and may decrease disease severity.  When injection of anti- 
body to or4 integrin (LPAM-1 and PS/2) was continued every 
3 d until after onset of disease,  not only was the onset of 
disease delayed, but in this case the severity of disease was 
also significantly decreased (data not shown). This decrease 
was not seen when the isotype-matched control antibody was 
injected every 3  d. 
Response to MBP Peptide Ac1-16 Segregates with Expression 
of  or4 Integrin on Lymph Node Cells  from Animals Primed with 
MBP,  All of the prior studies were carried out with a long- 
term in vitro cloned T  cell line. For comparison, recently 
isolated polydonal T cells specific for MBP were stained with 
antibody to c~4 integrin (LPAM-1) and sorted according to 
fluorescence intensity. Two populations that differ in or4 inte- 
grin expression were plated with syngendc feeder cells and 
varying amounts ofMBP peptide Ac1-16. As can be seen from 
Fig.  7, almost all of the reactivity to MBP peptide Ac1-16 
segregated with the r  integrin high population of cells. Thus, 
or4 integrin expression correlates with priming, and all re- 
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Figure 6.  The pathogenicity of clone 19 can be inhibited by mAbs specific 
for ct4 integrin, VCAM-1, and ICAM-1. 2  x  10  ? cells were incubated 
either in PBS or the specified antibody and injected into irradiated female 
(PL/J  x  SJL)F1 mice. (A) Clone 19I) treated with PBS (I), anti-c*4 lute- 
grin (LPAM-1, IgG2b [&]), and the isotype-matched control anti-CD44 
(PGF1, IgG2b [O]). (B) Clone 19 transferred with PBS (B), anti-VCAM-1 
given only at the time of injection of cells (O), or also on days 3 and 
6 (VCAM-t  x3 [A]). (c) Mice given clone 19 in PBS (.), with anti- 
ICAM-1 (YN1, IgG2a [&]), and the isotype-matched control, anti-CD45 
(TIB 122, IgGZa [0]). 
cently primed cells that can proliferate to antigen appear to 
express  high ix4 integrin levels in this system. 
The Pathogenicity of the MBP-?rimed Lymph Node Cells Can 
also Be Inhibited by mAbs Specific  for or4 Integrin.  To test the 
role of De4 integrin in EAE produced by primary lymph node 
ceils, the effect of anti-or4 integrin mAb on disease induced 
by  adoptive  transfer of lymph node cells  was  examined. 
2  x 10  7 MBP-primed lymph node cells were injected into fe- 
male irradiated (PL/J  x  SJL)F~ mice with and without an- 
tibody to ix4 integrin (LPAM-1). One group received LPAM-1 
only at the time of injection of lymph node cells, while an- 
other group received LPAM-1 at the time of injection of cells 
as well as on days 3 and 6 after injection of cells. As can be 
seen in Fig. 8, antibody to or4 integrin given once significantly 
delayed the onset of EAE, while in the group that rec.eived 
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Figure 7.  Proliferation of MBP-primed lymph node cells, sorted accord- 
ing to c,4 integrin expression, in response to APC plus MBP peptide Ac1-16. 
MBP-primed lymph node cells were sorted by FACS  ~ into c~4 integrin 
high (A) and low (e) popuhtions. Cells were plated in triplicate with 
APC and MBP peptide Ac1-16 at varying concentrations. Phtes were pulsed 
with [3H]thymidine after 72 h and harvested 15 h later. Data are expressed 
as cpm by subtraction of the background cpm in the absence of MBP Aci- 
16; these were 49 cpm for LN-VLA-4 low and 6,271 cpm for LN-VLA-4 
high. Draining inguinal, popliteal, and para-anrtic lymph nodes were iso- 
lated from (PL/J  x  SJL)F~ female mice 10 d after subcutaneous  injection 
ofS0/~g guinea pig MBP emulsified in CFA. Lymph nodes were separated 
into single cell suspension and cultured for 8 d in medium with syngeneic 
feeder cells, FCS, 25/~g/ml guinea pig MBP, and 10/~g/ml MBP peptide 
Ac1-16. 5 U/ml rlL-2 was added on day 3. 
continued injection of LPAM-1, disease was further delayed 
and the severity of disease was also diminished. 
Discussion 
The basic question we have sought to address in the present 
experiments is what determines the ability ofa T cell to enter 
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Figure 8.  The pathogenicity MBP-primed lymph node cells can also 
be inhibited by mAbs specific for ol4 integrin. 2  x  107 MBP-primed 
lymph node cells were incubated with either PBS (I) or antibody to c,4 
integrin (LPAM-1) and then injected into irradiated (PL/J  x  SJL)F1 fe- 
male mice, One group was given cells and LPAM-1 (O), one group was 
given ceils and LPAM-1 followed by two more doses of LPAM-1 on days 
3 and 6 (A), While a contrd group receiving no cells (e) did not develop 
disease. 
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specific  for an encephalitogenic peptide of MBP must secrete 
lymphotoxin (LT) to cause disease (29-31). Our initial results 
support these prior conclusions since in our studies CD4 + 
Th-1 ceils, which are specific for an encephalitogenic MBP 
peptide and secrete  large amounts of  IFN-q/and TNF-o~ and/or 
-/3, are encephalitogenic, while CD4 + Th-2 clones, which 
are specific  for the same encephalitogenic peptide but secrete 
large amounts of IL-4 and no IFN-3~ or LT, are unable to 
induce disease. 
Our studies add an additional requirement to those cited 
above; to cause disease, a CD4 cell must be able to leave the 
blood  and  enter the brain parenchyma.  We demonstrate 
that this requires cell surface VLA-4 binding to endothelial 
VCAM-1, and probably LFA-1 binding to endothelial ICAM-1 
as well. Several lines of evidence point to the idea that loss 
of encephalitogenic potential correlates with a decreased level 
of  cell surface VLA-4, and a corresponding loss of this ability 
of  the lymphocytes to enter the brain. The above  results found 
with a T call done appear to apply to undoned T lympho- 
cytes as well. In addition,  as VLA-4 is an activation antigen 
found on memory cells, specificity for MBP peptide Ac1-16 
cosegregates with expression of o~4 integrin on lymph node 
cells from animals primed with MBP. On this basis, naive 
T cells should not be able to enter brain, perhaps explaining 
the absence of tolerance to the neural antigen MBP. 
If c~4 integrin expression is required for disease, what is 
its role in pathogenesis? It seems unlikely that VLA-4 is re- 
quired for T cell activation in EAE, since  both the encephalito- 
genic done 19P and its nonencephalitogenic  variant  clone 
19B respond equivalently to MBP peptide Ac1-16 in terms 
of proliferation and lymphokine production, and antibodies 
to c~4 integrin do not block this response in vitro. A more 
likely role for c~4 integrin in the pathogenesis of EAE would 
be in allowing lymphocytes access to the CNS. This is sup- 
ported by the demonstration that pathogenic sublines of  clone 
19 bind strongly to endothelial cells and VCAM-1 and enter 
into brain parenchyma, while nonpathogenic sublines of clone 
19 bind weakly to endothelial cells and VCAM-1 and are found 
in brain only in ependymal tissue. This idea is further sup- 
ported by the fact that antibodies to c~4 integrin, VCAM-1, 
and ICAM-1  appear to inhibit pathogenicity by excluding 
lympbocytes from the CNS. However, when antibody levels 
decline, the animals become sick. 
It has been proposed that lymphocyte  entry into the CNS 
is initiated  when an activated CNS antigen-specific  T  cell 
binds to endothelium by LFA-I-ICAM-1 interaction (57, 58). 
Our data are compatible with this, as anti-ICAM-1 inhibits 
disease effectively. We propose that once the T cell binds to 
endothelium, whether it be by an LFA-I-ICAM-1 interac- 
tion or by sdectin binding, the activated cell induces upregu- 
lation of  VCAM-1 on the endothelium by virtue of  its produc- 
tion of IFN-3, and both soluble and membrane-bound LT 
and TNF. In this regard, we have observed staining of en- 
dothelium with anti-VCAM-1 where perivascular cuffs are 
present (data not shown). The activated T lymphocyte  must 
have surface expression of V'LA-4 to bind to this newly in- 
duced VCAM-1  and enter into the CNS.  This hypothesis 
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would predict that a T lymphocyte that can enter into the 
CNS must be able to secrete appropriate  lymphokines for 
upregulation of  adhesion molecules and must express VLA-4 
and LFA-1. This is consistent with the failure of  naive T, Th2, 
rested Thl, or activated Thl calls with decreased production 
of LT/TNF or IFN-'y to enter the CNS on their own. Most 
importantly for this study, cells  with decreased  levels of  V'LA-4 
could not cross the brain endothdium. It is likely that only 
a small number of lymphocytes need to cross the endothdial 
barrier initially, and that the majority of  lymphocytes present 
in the inflammatory  lesions are the progeny of those few cells 
that originally  entered the tissue or are recruited by local 
inflammation  triggered by the early immigrants. 
A more general conclusion suggested by these studies, but 
not directly addressed in them, is that VLA-4 is involved in 
immune surveillance of many tissues including the CNS. We 
suggest that the c~4 integrins play a crucial role in the emigra- 
tion of  recently activated lymphocytes from blood into tissues. 
If specific antigen is present in the tissues, then the lympho- 
cyte would remain in the tissue and in responding to antigens 
would activate local endothdium to recruit further effector 
cells. This mechanism would allow effector lymphocytes to 
reach sites of infection involving pathogens that do not nor- 
mally elicit inflammation,  such as certain viruses. This con- 
dusion attributes  to c~4 integrins  a role in the differential 
migration of activated or memory  T cells described by McKay 
et al. (18). 
A recent paper suggests that both VLA-4 and CD44 confer 
the ability of a CD8 + clone specific for a peptide from a 
rodent malaria species to be protective against malarial infec- 
tion (59). We did not detect a role of CD44 in the pathogen- 
esis of EAE, since both the encephalitogenic and nonenceph- 
alitogenic sublines of  a T cell clone expressed equivalent levels 
of CD44. More important, in vivo studies using antibodies 
to CD44 had no effect on the pathogenesis of  EAE. Another 
recent study has also suggested a role for VLA-4 in rat EAE 
(60). Unlike our studies, these earlier studies did not examine 
VLA-4 expression as a critical component of encephalogenic 
potential,  and did not follow disease beyond 7 d. Thus, it 
is unclear whether disease in that model was delayed (as in 
our studies) or totally prevented by anti-VLA-4. Moreover, 
that study concluded that VLA-4 may be crucial  for nonspecific 
leukocyte recruitment, whereas our studies point strongly 
to a role for VLA-4 in the entry of specific  T cells into brain 
and did not address its role in recruitment. In addition, other 
recent studies have suggested a role for VLA-4 in the passage 
ofT cells  from blood into sites of  inflammation (61-63). These 
studies are consistent with our results, but did not address 
the issue of how activated T cells enter tissues in the absence 
of an inflammatory stimulus,  the main focus of our experi- 
ments.  Taken together, the results of all these studies sup- 
port the hypothesis that VLA-4 is a crucial mediator of  effector 
T cell emigration from blood into infected tissues. Finally, 
as we have also observed modulation of VLA-4 expression 
in vivo when cloned T cells migrate from perivascular cuffs 
into brain parenchyma, the regulated expression of this and 
other integrins may have importance in effector  T cell function. We thank Paul Kincade and Irv Weissman for providing mAbs, and Roy Lobb for providing mAbs and 
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